Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
Autore:
Atkins, MB; Lotze, MT; Dutcher, JP; Fisher, RI; Weiss, G; Margolin, K; Abrams, J; Sznol, M; Parkinson, D; Hawkins, M; Paradise, C; Kunkel, L; Rosenberg, SA;
Indirizzi:
NCI, Cytokine Working Grp, Bethesda, MD 20892 USA NCI Bethesda MD USA 20892 I, Cytokine Working Grp, Bethesda, MD 20892 USA NCI, Surg Branch, Bethesda, MD 20892 USA NCI Bethesda MD USA 20892NCI, Surg Branch, Bethesda, MD 20892 USA Chiron Corp, Emeryville, CA 94608 USA Chiron Corp Emeryville CA USA 94608Chiron Corp, Emeryville, CA 94608 USA
Titolo Testata:
JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 7, volume: 17, anno: 1999,
pagine: 2105 - 2116
SICI:
0732-183X(199907)17:7<2105:HRI2TF>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
COOPERATIVE-ONCOLOGY-GROUP; RENAL-CELL CARCINOMA; ACTIVATED KILLER CELLS; MALIGNANT-MELANOMA; RANDOMIZED TRIAL; INTERFERON ALFA-2B; PROGNOSTIC FACTORS; PHASE-II; DACARBAZINE; COMBINATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
50
Recensione:
Indirizzi per estratti:
Indirizzo: Atkins, MB Beth Israel Deaconess Med Ctr, Div Hematol & Oncol, 330 Brookline Ave,EKS-158, Boston, MA 02215 USA Beth Israel Deaconess Med Ctr 330 Brookline Ave,EKS-158 Boston MA USA 02215
Citazione:
M.B. Atkins et al., "High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993", J CL ONCOL, 17(7), 1999, pp. 2105-2116

Abstract

Purpose: To determine the short- and long-term efficacy and toxicity of the high-dose intravenous bolus interleukin 2 (IL-2) regimen in patients withmetastatic melanoma,Patients and Methods: Two hundred seventy assessable patients were enteredonto eight clinical trials conducted between 1985 and 1993. IL-2 (Proleukin [aldesleukin]; Chiron Corp, Emeryville, CA) 600,000 or 720,000 IU/kg was administered by 15-minute intravenous infusion every 8 hours for up to 14 consecutive doses over 5 days as clinically tolerated with maximum support, including pressors, A second identical treatment cycle was scheduled after 6 to 9 days of rest, and courses could be repeated every 6 to 12 weeks in stable or responding patients, Data were analyzed through fall 1996. Results: The overall objective response rate was 16% (95% confidence interval, 12% to 21%); there were 17 complete responses (CRs) (6%) and 26 partial responses (PRs) (10%), Responses occurred with ail sites of disease and in patients with large tumor burdens. The median response duration for patients who achieved a CR has not been reached and was 5.9 months for those whoachieved a PR, Twelve (28%) of the responding patients, including 10 (59%)of the patients who achieved a CR, remain progression-free. Disease did not progress in any patient responding for more than 30 months. Baseline performance status and whether patients had received prior systemic therapy were the only predictive prognostic factors for response to IL-2 therapy. Toxicities, although severe, generally reversed rapidly after therapy was completed. Six patients (2%) died from adverse events, all related to sepsis,Conclusion: High-dose IL-2 treatment seems to benefit some patients with metastatic melanoma by producing durable CRs or PRs and should be consideredfor appropriately selected melanoma patients. (C) 1999 by American Societyof Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 09:57:43